GlassScriptPhysician profile
Madiha Ali
NPI 1083233373
$5,136.26
in general payments reported to CMS, 2019-2025
29 companies · $1,998 in 2025
The $1,998 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,004 · 2024: $2,134 · 2025: $1,998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,136.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $805.21 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $803.92 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $616.70 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $612.07 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $607.95 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.18 | 2023-2025 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $163.31 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $152.78 | 2023-2024 | Xarelto |
| Axsome Therapeutics, INC. | $144.45 | 2023-2025 | Sunosi |
| Abbvie INC. | $139.46 | 2024-2025 | |
| Exact Sciences Corporation | $138.69 | 2023-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $86.59 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $69.54 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $66.92 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $58.76 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $57.97 | 2024-2025 | Otezla, Evenity, Repatha |
| Inspire Medical Systems, INC. | $49.79 | 2023-2025 | Inspire |
| Sumitomo Pharma America, INC. | $42.61 | 2023-2024 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $35.61 | 2023-2024 | |
| Watermark Medical, INC. | $31.53 | 2024 | |
| Eisai INC. | $31.39 | 2024 | |
| Lucid Diagnostics INC. | $31.38 | 2024 | |
| Medtronic, INC. | $28.14 | 2025 | Closurefast |
| Abbott Laboratories | $24.24 | 2025 | Freestyle Libre 3 |
| Tonix Medicines, INC. | $22.91 | 2025 | Tonmya |
| Ars Pharmaceuticals Operations, INC. | $20.36 | 2025 | Neffy |
| Dexcom, INC. | $18.24 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $14.90 | 2025 | Gvoke Hypopen |
| Paratek Pharmaceuticals, INC. | $14.66 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madiha Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.